A Study of Ralinepag in Healthy Chinese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

November 9, 2020

Study Completion Date

November 9, 2020

Conditions
Healthy VolunteerPharmacokinetic Study
Interventions
DRUG

Ralinepag

"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Everstar Medicines (Shanghai) Limited

INDUSTRY

NCT04613999 - A Study of Ralinepag in Healthy Chinese Adult Subjects | Biotech Hunter | Biotech Hunter